Financial Performance - The company reported a significant increase in revenue, achieving a total of CNY 1.5 billion in the first half of 2023, representing a year-on-year growth of 25%[2]. - For the six months ended June 30, 2023, revenue was RMB 3,756,335, a significant increase compared to RMB 1,218,477 for the same period in 2022[12]. - Total revenue for the six months ended June 30, 2023, was RMB 2,706,246, a decrease of 28.0% compared to RMB 3,756,335 in 2022[49]. - Profit for the period decreased to RMB 122,366 from RMB 510,404 in the previous year, indicating a decline in profitability[12]. - The profit attributable to equity holders decreased by 75.9% to RMB 123.3 million, while adjusted profit excluding investment losses increased to RMB 340.3 million[18]. - The total comprehensive income for the period was RMB 230,198,000, a decline of 67% compared to RMB 701,063,000 in the previous year[119]. - Profit before tax decreased to RMB 167.7 million, compared to RMB 629.0 million in the prior year, representing a decline of approximately 73.3%[117]. User Growth and Market Expansion - User data showed a 30% increase in active users, reaching 2 million by the end of June 2023[2]. - Market expansion plans include entering two new international markets by Q4 2023, targeting an additional CNY 500 million in revenue[2]. - The company provided a positive outlook for the second half of 2023, projecting a revenue growth of 20% to 25%[2]. Product Development and R&D - The company is investing CNY 200 million in R&D for new technologies aimed at enhancing product efficacy[2]. - New product launches are expected to contribute an additional CNY 300 million in revenue by the end of 2023[2]. - The Group has obtained exclusive development and commercial rights in China for certain clinical stage innovative drug candidates targeting immune system-related diseases[14]. Cost Management and Profitability - The gross margin improved to 55%, up from 50% in the previous year, due to cost optimization strategies[2]. - The company aims to reduce operational costs by 10% through efficiency improvements in the supply chain[2]. - The gross profit for the same period was RMB 2,706,246, resulting in a gross profit margin of 35.4%, up from 32.4% in 2022[12]. - The Group's heparin industrial chain business achieved sales revenue of RMB 2,289.5 million, down from RMB 3,268.9 million in the same period last year[21]. Strategic Initiatives - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of CNY 1 billion allocated for potential deals[2]. - A new strategic partnership was announced, expected to enhance distribution channels and increase market penetration[2]. - The Group's subsidiary Techdow USA Inc. entered into a distribution agreement with Chia Tai Tianqing Pharmaceutical Group, aligning with the Group's internationalization strategy[19]. Financial Position and Assets - Total assets as of June 30, 2023, were RMB 20,787,431, slightly down from RMB 20,814,204 at the end of 2022[12]. - The equity attributable to owners of the parent increased to RMB 12,397,624 from RMB 12,310,915, reflecting a positive trend in shareholder equity[12]. - The asset-liability ratio improved to 39.9% from 40.4%, indicating a stronger financial position[12]. Market Conditions and Economic Outlook - The global economic growth forecast for 2023 was lowered to 3.0%, with developed economies expected to grow only 1.5%[15]. - China's GDP growth for the first and second quarters of 2023 was reported at 4.5% and 6.3% year-on-year, showing significant recovery[15]. Shareholder Information and Corporate Governance - The Board consists of six Directors, including three executive Directors and three independent non-executive Directors[80]. - The company has complied with all applicable provisions of the Corporate Governance Code during the reporting period[109]. - The company declared dividends to shareholders, reflecting ongoing shareholder returns[128]. Financial Instruments and Risks - The Group reported a tax-adjusted unrealized foreign exchange gain of RMB 79.1 million during the reporting period[68]. - The Group plans to utilize financial market tools to mitigate foreign exchange loss risks and will actively promote internal loan conversion approval processes[68]. - The company reported foreign exchange losses of RMB 126,847, compared to losses of RMB 102,886 in the same period of 2022, indicating an increase of 23.3%[196].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. （深圳市海普瑞藥業集團股份有限公司） （於中華人民共和國註冊成立的股份有限公司） （股份代號：9989） 截至二零二三年六月三十日止六個月之中期業績公告 深圳市海普瑞藥業集團股份有限公司（「本公司」、「公司」或「海普瑞」）董事會（「董 事會」）欣然宣佈本公司及其子公司（「本集團」或「我們」）截至二零二三年六月三十 日止六個月（「報告期」）之未經審核綜合中期業績，連同二零二二年同期的比較數字。 | --- | --- | --- | --- | --- | |-------------------------------------------------------------------------------------------|-------|--------------------------- ...

经与会董事认真审议并通过了以下议案： 证券代码：002399 证券简称：海普瑞 公告编号：2023-036 深圳市海普瑞药业集团股份有限公司 第六届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳市海普瑞药业集团股份有限公司（以下简称"公司"）第六届董事会第 二次会议（以下简称"会议"）通知及议案于2023年8月16日以电子邮件的形式 发出，会议于2023年8月21日14:00以通讯方式召开。本次会议应参与表决董事7 人，实际以通讯方式参与表决董事7人。公司监事及高级管理人员列席会议，会 议由公司董事长李锂先生主持。本次会议的通知、召开以及参与表决董事人数均 符合相关法律法规及《公司章程》的有关规定。 附件：财务总监陈娟简历 陈娟女士，1975年生，中国国籍，无境外永久居留权，湖北大学经济学学士， 清华大学会计硕士，拥有CGMA全球特许管理会计师和FIPA澳大利亚资深公共 会计师资格证，具备超过20年大型跨国上市企业财务管理经验。2012年-2015年 先后任IBM系统集成（深圳）有限公司和联想系统集成（深圳）有限公司财务总 监； ...

深圳市海普瑞药业集团股份有限公司 证券代码：002399 证券简称：海普瑞 公告编号：2023-037 公司于2023年8月21日召开第六届董事会第二次会议，审议通过了《关于聘 任陈娟女士为公司财务总监的议案》，同意聘任陈娟女士为公司财务总监（简历 附后），任期自本次董事会审议通过之日至公司第六届董事会任期届满之日止。 关于变更财务总监的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、财务总监辞职 深圳市海普瑞药业集团股份有限公司（以下简称"公司"）董事会于近日收 到公司财务总监向贤青先生的书面辞职报告。向贤青先生因个人工作安排申请辞 去公司财务总监职务。辞职后，向贤青先生不再担任公司任何职务。 根据《公司法》、《公司章程》等有关规定，向贤青先生的辞职报告自送达董 事会之日起生效。截至本公告披露日，向贤青先生未持有公司股份。 公司对向贤青先生任职期间为公司发展所做出的贡献表示衷心感谢。 二、聘任财务总监 公司独立董事就该事项发表了独立意见，同意聘任陈娟女士为公司财务总监。 《公司独立董事关于第六届董事会第二次会议相关事项的独立意见》刊登于信息 披露媒 ...

独立董事：吕川、黄鹏、易铭 二〇二三年八月二十二日 1 一、关于聘任陈娟女士为公司财务总监的议案 经审阅陈娟女士的履历材料，未发现有《公司法》第 146、147、148 条规定的 情况以及被中国证监会确定为市场禁入者，并且禁入尚未解除之现象，其任职资格 符合担任上市公司高级管理人员的条件，能够胜任所聘财务总监职务，公司提名、 聘任的程序符合《公司法》、《公司章程》的有关规定，合法有效。因此，我们同意 聘任陈娟女士为公司财务总监，任期自董事会审议通过之日至第六届董事会任期届 满之日止。 深圳市海普瑞药业集团股份有限公司独立董事 关于第六届董事会第二次会议相关事项的独立意见 根据《上市公司独立董事规则》、《深圳证券交易所上市公司自律监管指引第 1号——主板上市公司规范运作》及《公司章程》、公司《独立董事工作制度》的 有关规定，作为深圳市海普瑞药业集团股份有限公司（以下简称"公司"）的独立 董事，我们对第六届董事会第二次会议审议的相关议案进行审阅，现对相关事项发 表独立意见如下： ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥1,301,021,684.04, a decrease of 31.90% compared to ¥1,910,323,745.74 in the same period last year[3]. - Net profit attributable to shareholders was ¥66,540,023.25, down 71.68% from ¥234,943,371.65 year-on-year[3]. - The net cash flow from operating activities was negative at ¥213,979,198.80, a significant decline of 15,418.93% compared to the previous year[3]. - Basic and diluted earnings per share were both ¥0.0453, reflecting a decrease of 71.71% from ¥0.1601 in the same period last year[3]. - Gross profit for the current period was RMB 454.0 million, down from RMB 579.2 million year-on-year, with a gross margin of 34.9%, up from 30.3%[12]. - Operating profit decreased by 74.02% to RMB 73.6 million, primarily due to a reduction in gross profit[9]. - The total comprehensive income for the current period is CNY 61,856,551.06, a decrease from CNY 230,706,330.71 in the previous period[32]. Assets and Liabilities - Total assets at the end of the reporting period were ¥20,623,022,731.91, a decrease of 0.92% from ¥20,814,206,782.52 at the end of the previous year[3]. - Total liabilities increased from CNY 8,406,564,448.47 to CNY 8,435,034,680.42, with an adjustment of CNY 28,470,231.95[24]. - Total assets amount to RMB 20,623,022,731.91, down from RMB 20,814,206,782.52, indicating a decrease of 0.9%[29]. - Total liabilities decreased to RMB 8,151,172,088.52 from RMB 8,406,564,448.47, reflecting a reduction of 3.0%[29]. - Non-current liabilities increased to RMB 3,016,772,193.42 from RMB 2,830,768,147.44, representing a growth of 6.6%[29]. Cash Flow - The company experienced a significant increase in cash flow from investment activities, reporting a net cash inflow of RMB 795.7 million, compared to a net outflow of RMB 88.0 million in the same period last year, representing a 1,003.94% increase[10]. - Cash inflow from operating activities is CNY 1,936,382,607.31, a slight decrease from CNY 1,964,042,020.61 in the previous period[34]. - Cash outflow from operating activities totals CNY 2,150,361,806.11, compared to CNY 1,965,420,847.89 in the previous period[35]. - Net cash flow from investment activities is CNY 795,650,734.04, a significant improvement from CNY -88,020,516.24 in the previous period[36]. - Net cash flow from operating activities is negative at CNY -213,979,198.80, compared to CNY -1,378,827.28 in the previous period[35]. Market and Sales Strategy - The company’s heparin sodium product sales volume and market share have rapidly increased over the past five years, becoming a key revenue growth driver[11]. - The company plans to strengthen its sales layout in Europe, where it holds a top two market share position, and will continue to expand its presence in untapped markets[13]. - The company is actively pursuing diversified marketing strategies and expanding sales territories to overcome current challenges[14]. - The company aims to optimize its supply chain management and resource distribution to support the expansion of its main business[11]. - The company received FDA approval for its heparin sodium injection, allowing for self-marketing in the U.S. market, marking a significant breakthrough[12]. Shareholder Information - The top ten shareholders hold significant stakes, with Shenzhen Lerun Technology Co., Ltd. owning 32.31% and Urumqi Jintian Investment Partnership holding 27.81%[18]. - The top ten shareholders include Shenzhen Le Ren Technology Co., holding 474,029,899 shares, and Urumqi Jintian Equity Investment Partnership, holding 408,041,280 shares, indicating strong institutional support[19]. Research and Development - Research and development expenses for the current period are RMB 26,514,765.57, an increase of 27.1% compared to RMB 20,883,937.48 in the previous period[30]. - The CDMO business is driven by Cytovance Biologics, Inc. and SPL Acquisition Corp., focusing on integrating R&D resources and enhancing customer collaboration[15]. Strategic Collaborations - The company entered a licensing agreement with Youhua Biotech for the commercialization of Oregovomab in Taiwan, enhancing its strategic partnerships in the Greater China region[20]. - The company’s subsidiary Tian Dao America signed a distribution agreement with Zhengda Tianqing for the commercialization of Fosaprepitant in the US, marking a significant step in its overseas marketing efforts[20].

Financial Performance - Revenue for 2022 reached RMB 7,151,039, an increase of 12.4% compared to RMB 6,359,786 in 2021[6] - Profit before tax for 2022 was RMB 829,851, representing a 273.5% increase from RMB 222,264 in 2021[6] - Profit attributable to owners of the Company for the year was RMB 727,077, up from RMB 240,788 in 2021, marking a significant increase of 202.5%[6] - For the year ended December 31, 2022, the Group achieved operating revenue of RMB 7,151 million, representing an increase of 12.4% compared to the previous year[11] - The gross profit margin for the year was 32.0%, an increase of 0.7 percentage points from the previous year[11] - Profit attributable to owners of the Company amounted to RMB 727.1 million, reflecting a year-on-year growth of 202.0%[12] - The sales of finished dose pharmaceutical products increased by 21.7% to RMB 3,210.5 million, while API sales decreased by 1.8% to RMB 2,673.8 million[27] - The CDMO service segment saw a significant growth of 33.3%, with operating income reaching RMB 1,084.1 million[27] - The Group's gross profit margin improved compared to the previous year, indicating better cost control and operational efficiency[24] - The Group's financial summary for the last five financial years is available on page 5 of the annual report[84] Assets and Liabilities - Total assets as of 2022 amounted to RMB 20,814,204, an increase from RMB 19,108,177 in 2021[7] - Total liabilities increased to RMB 8,406,565 in 2022, compared to RMB 7,584,862 in 2021[7] - Equity attributable to shareholders of the Company was RMB 12,310,915 in 2022, up from RMB 11,411,354 in 2021[7] - The asset-liability ratio was approximately 40.4% as of December 31, 2022, compared to approximately 39.7% as of December 31, 2021[55] - The Group's interest-bearing borrowings amounted to approximately RMB 6,317.5 million as of December 31, 2022, up from approximately RMB 5,518.4 million as of December 31, 2021[62] Market Expansion and Strategy - The Company plans to expand its market presence and invest in new product development in the upcoming year[6] - The management highlighted ongoing research and development efforts aimed at enhancing product offerings and technological advancements[6] - The Company is exploring potential mergers and acquisitions to strengthen its market position and drive growth[6] - Hepalink aims to enhance its digitalization capabilities and build an integrated production and sales model to improve operational efficiency and reduce costs[15] - The Group plans to strengthen its supply chain management to effectively control procurement costs and improve profit margins[15] - The Company is committed to becoming a leading innovative multinational pharmaceutical company globally by strengthening its core competencies[15] Sales and Distribution - Global sales volume in 2022 exceeded 227 million units, up 22.3% year-on-year, while sales revenue increased by 12.4% compared to the same period last year[12] - The Company achieved sales expansion in over 30 provinces and cities in China and entered into drug procurement catalogs of various regions[12] - Sales in the U.S. market maintained steady growth, with the Group's enoxaparin sodium finished doses becoming a market leader, supported by contracts with the three largest distributors and major Group Purchasing Organizations[30] - Sales in the China market exceeded 13 million units, representing an increase of more than 50%, with successful expansion into over 30 provinces and cities nationwide[30] - The Group's enoxaparin sodium injection brand, Prolongin, became the first to achieve online sales cooperation with multiple internet platforms in China[30] Research and Development - Hepalink has obtained exclusive development and commercial interest in Greater China for certain clinical stage innovative drug candidates targeting immune system diseases[17] - The global Phase III study of AR-301 enrolled 174 subjects, with 120 cases in the modified intention to treat (mITT) analysis, showing benefits for patients over 65 years old[37] - Oregovomab demonstrated a median progression-free survival (PFS) of 41.8 months in combination with chemotherapy, compared to 12.2 months for chemotherapy-only, with a hazard ratio (HR) of 0.46[37] - The critical technology R&D project for H1710 has been approved by the Science, Technology and Innovation Commission of Shenzhen[38] - The company is focused on innovative drug R&D, ensuring effective allocation and management of resources for clinical development[44] Corporate Governance - The Company aims to achieve good corporate governance standards to safeguard shareholder interests and enhance corporate value[149] - The Board comprises 6 Directors, including 3 executive Directors and 3 independent non-executive Directors[150] - The roles of Chairman and Chief Executive Officer are held by different individuals, ensuring compliance with governance standards[152] - The Company has received written annual confirmations of independence from all independent non-executive Directors, affirming their independence[152] - The Company has established a code of conduct for securities trading by its directors and senior management, ensuring compliance with required standards[149] Shareholder Engagement - The Company has established a shareholders' communication policy to ensure effective engagement with shareholders and regular reviews of its effectiveness[186] - The Board considers the implementation and effectiveness of the shareholders' communication policy to be sufficient and adequate during the reporting period[187] - The Company aims to maintain ongoing dialogue with shareholders through annual general meetings and other meetings[186] - The Group's largest customer accounted for 10.3% of total revenue, while the five largest customers contributed 31.7% of total revenue during the reporting period[140] Risk Management - The Company has established a robust internal control system to manage various potential risks related to its strategic plan, research and development, and other operational aspects[176] - The Board has reviewed the risk management and internal control systems and deemed them effective and adequate for the Reporting Period[177] - The Company has implemented measures to manage potential conflicts of interest between the Group and its Controlling Shareholders[176] - The Company faces risks related to market acceptance, pricing controls, and reimbursement policies that could adversely affect operations and profitability[146] Future Outlook - The global macroeconomic environment in 2023 is expected to be challenging, with China's economic rebound contrasting with recession risks in Europe and the U.S.[39] - The Company is optimistic about future prospects and will continue to implement its existing strategy while exploring new opportunities for business breakthroughs[45] - The management has set a revenue target of $500 million for the upcoming fiscal year, representing a 10% increase from the current year[64]

证券代码：002399 证券简称：海普瑞 公告编号：2023-027 深圳市海普瑞药业集团股份有限公司 关于举行2022年度网上业绩说明会的公告 一、业绩说明会召开时间及投资者参与方式 时间：2023年4月14日（星期五）下午15:00-16:30 召开方式：网络 参与方式：投资者可通过"同花顺路演平台"（http://board.10jqka.com.cn/rs/） 或同花顺App端入口（同花顺App首页-搜索-路演平台）参与本次年度业绩说明 会 二、公司出席人员 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 公司董事长李锂先生、董事兼总经理单宇先生、独立董事吕川先生、董事会 秘书钱风奇先生及财务总监向贤青先生。 深圳市海普瑞药业集团股份有限公司（以下简称"公司"）将于2023年4月 14日（星期五）通过"同花顺路演平台"举行2022年度业绩网上说明会，具体如 下： 三、问题征集 （问题征集专题页面二维码） 欢迎广大投资者积极参与本次网上业绩说明会。 特此公告。 深圳市海普瑞药业集团股份有限公司 董事会 二〇二三年四月十二日 为充分尊重投资者、提升交流的针 ...

Revenue and Profitability - Revenue increased by 12.4% to RMB 7,151.0 million (2021: RMB 6,359.8 million) [2] - Profit attributable to equity holders of the parent increased by RMB 486.3 million or 202.0% to RMB 727.1 million [2] - Net profit attributable to equity holders increased by 202.0% to RMB 727.1 million, with basic earnings per share rising to RMB 0.50 from RMB 0.16 in 2021 [11] - Gross profit was RMB 2,290.2 million (2021: RMB 1,993.6 million), with a gross margin of 32.0%, up 0.7 percentage points [2] - Gross profit increased by RMB 296.6 million to RMB 2,290.2 million, compared to RMB 1,993.6 million in the same period last year, with a gross margin rise from 31.3% to 32.0% [38] Business Segments Performance - Formulation business sales revenue grew by 21.7% to RMB 3,210.5 million (2021: RMB 2,638.2 million) [2] - CDMO business sales revenue increased by 33.3% to RMB 1,084.1 million (2021: RMB 813.1 million) [2] - The pharmaceutical formulation segment achieved a revenue growth of 21.7%, totaling approximately RMB 3,210.5 million, accounting for 44.9% of total revenue [15] - CDMO services revenue grew by 33.3% to RMB 1,084.1 million, indicating strong demand in this segment [13] - The API business generated approximately RMB 2,673.8 million in sales revenue, accounting for 37.4% of total revenue, with a gross margin improvement to 27.7% [19] Market Expansion and Strategy - The company has established exclusive development and commercialization rights for several innovative drug candidates in Greater China, focusing on immune-related diseases [10] - The supply chain strategy has been enhanced to ensure material supply and operational efficiency amid global economic challenges [10] - The company is actively developing proprietary drug candidates currently in the preclinical stage [10] - The company actively expanded its market presence in France and Switzerland, further solidifying its position in Europe [16] - The company achieved significant sales growth in emerging markets such as Malaysia, Brazil, and Saudi Arabia, while also advancing international drug registration efforts [17] Financial Position and Assets - Total assets less current liabilities amounted to RMB 15,238.4 million (2021: RMB 14,316.7 million) [7] - Net assets attributable to equity holders of the parent increased to RMB 12,310.9 million (2021: RMB 11,411.4 million) [7] - Total assets as of December 31, 2022, were approximately RMB 20,814.2 million, compared to RMB 19,108.2 million as of December 31, 2021 [46] - Total liabilities as of December 31, 2022, were approximately RMB 8,406.6 million, compared to RMB 7,584.9 million as of December 31, 2021, resulting in a debt-to-asset ratio of approximately 40.4% [46] Dividends and Shareholder Returns - The board declared a final cash dividend of RMB 1.0 per ordinary share (tax included) for the year [2] - The proposed final dividend per ordinary share for 2022 is RMB 0.10, compared to RMB 0.035 in 2021, representing an increase of 185.7% [77] - The final dividend will be distributed to H shareholders no later than August 15, 2023, if approved [87] - The annual general meeting is scheduled for May 22, 2023, where the dividend proposal will be discussed [88] Research and Development - The AR-301 monoclonal antibody is currently in global Phase III clinical trials, with 174 subjects enrolled, showing promising results in reducing mechanical ventilation time for patients with ventilator-associated pneumonia [24] - Oregovomab's Phase II clinical trial demonstrated a median progression-free survival (PFS) of 41.8 months compared to 12.2 months for the control group, with a hazard ratio (HR) of 0.46 [25] - RVX-208 has completed Phase III trials and received FDA breakthrough therapy designation, aiming to reduce major adverse cardiovascular events in high-risk patients [27] - H1710, an acetyl heparinase inhibitor, has completed active pharmaceutical ingredient production and is preparing for IND application in both China and the US [28] Operational Efficiency and Cost Management - The sales cost increased by RMB 494.7 million to RMB 4,860.9 million, primarily due to rising costs in pharmaceutical formulations and CDMO services [35] - Financing costs rose by RMB 35.5 million to RMB 245.6 million, an increase of 16.9% compared to RMB 210.1 million in the same period last year [39] - The company aims to enhance global supply chain management and digital integration to improve operational efficiency and resilience [29] Compliance and Governance - The audit committee reviewed the consolidated annual performance for the year ended December 31, 2022, and confirmed compliance with relevant accounting standards [92] - The company's auditor confirmed that the financial figures in the performance announcement are consistent with the consolidated financial statements [93] - There are no post-reporting period matters requiring shareholder attention [94]

Financial Performance - Total revenue for Q3 2022 reached ¥1,636,515,303.73, representing a year-over-year increase of 7.83%[3] - Net profit attributable to shareholders for Q3 2022 was ¥141,118,351.11, up 14.41% compared to the same period last year[3] - The net profit excluding non-recurring gains and losses for Q3 2022 was ¥122,989,129.35, showing a slight decrease of 0.23% year-over-year[3] - Basic earnings per share for Q3 2022 were ¥0.0962, an increase of 14.39% year-over-year[3] - The company achieved a total sales revenue of RMB 5,395.2 million, an increase from RMB 4,631.3 million in the same period last year, representing a growth of 16.6%[13] - Gross profit for the period was RMB 1,740.6 million, compared to RMB 1,456.6 million in the previous year, indicating a growth of 19.5%[13] - Net profit attributable to shareholders was RMB 652.3 million, up from RMB 461.5 million year-on-year, reflecting a growth of 41.3%[13] - Operating profit rose by 50.33% to RMB 841.9 million, driven by increased gross profit and foreign exchange gains[9] - Net profit for the period was ¥650,063,599.37, representing a 42.3% increase from ¥457,062,547.37 in the previous period[27] Cash Flow - Cash flow from operating activities showed a significant decline, with a net cash outflow of ¥719,281,089.84, a decrease of 686.10% compared to the previous year[3] - The net cash flow from operating activities decreased by 686.10% to a negative RMB 719.3 million, primarily due to increased cash payments for goods and services[11] - Cash inflow from operating activities for the current period is 6,083,780,203.37 RMB, up from 5,014,053,179.06 RMB in the previous period, representing an increase of approximately 21.4%[30] - Cash outflow from operating activities for the current period totals 6,803,061,293.21 RMB, compared to 4,891,330,630.26 RMB in the previous period, indicating a significant increase of approximately 39.1%[31] - The net cash flow from operating activities for the current period is -719,281,089.84 RMB, a decrease from 122,722,548.80 RMB in the previous period[31] - Cash inflow from financing activities for the current period is 4,939,819,789.90 RMB, compared to 2,890,440,715.27 RMB in the previous period, indicating an increase of approximately 71.0%[32] - The net cash flow from financing activities for the current period is 970,216,608.77 RMB, a significant improvement from -467,723,955.63 RMB in the previous period[32] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥21,469,099,221.29, reflecting a 12.36% increase from the end of the previous year[3] - The total current assets as of September 30, 2022, amount to ¥12,883,683,738.73, an increase from ¥10,769,653,462.96 at the beginning of the year[22] - Total liabilities rose to ¥8,997,212,942.94, up 18.6% from ¥7,584,859,851.21 in the previous period[25] - The total equity attributable to shareholders reached ¥12,361,047,485.93, an increase of 8.3% from ¥11,411,354,455.88[25] - The total liabilities to equity ratio stands at approximately 0.73, indicating a balanced capital structure[25] Inventory and Borrowings - Inventory increased by 38.15% year-over-year, reaching ¥6,503,409,988.32, attributed to strategic raw material reserves and anticipated market demand growth[6] - Short-term borrowings rose by 61.53% to ¥3,046,828,803.75, primarily due to increased bank loans during the reporting period[6] - The company's short-term borrowings have risen to ¥3,046,828,803.75 from ¥1,886,284,700.56, reflecting an increase of approximately 61.4%[23] Research and Development - Research and development expenses increased by 52.92% to RMB 166.6 million, attributed to direct investment increases[8] - Research and development expenses increased to ¥166,593,528.66, compared to ¥108,939,733.97 in the prior period, reflecting a growth of 53.1%[26] Market Performance - The heparin industry chain business achieved sales revenue of RMB 4,611.3 million, a 13.6% increase from RMB 4,054.5 million in the same period last year[14] - Sales revenue from enoxaparin sodium formulations reached approximately RMB 2,315.2 million, representing a 31.1% growth compared to RMB 1,765.6 million last year, with sales volume increasing by 32.7%[14] - The European market sales volume grew by 26.2%, despite currency fluctuations impacting sales[14] - The U.S. market saw a 144.6% increase in sales volume through a combination of partner and self-operated sales models[14] - Sales from the heparin raw material business amounted to approximately RMB 2,208.6 million, a 1.5% increase from RMB 2,176.0 million last year[14] - CDMO business sales reached approximately RMB 749.9 million, a 37.5% increase from RMB 545.0 million in the previous year[15] Strategic Initiatives - The company continues to strengthen relationships with existing clients and optimize supply chain management to support growth objectives[13] - The company plans to strengthen marketing and market development for enoxaparin sodium formulations, particularly in Europe and the U.S.[17] - The company aims to enhance its supply chain management and maintain cost advantages to improve financial performance amid economic uncertainties[16] - The company will continue to explore new customer opportunities in the CDMO sector and enhance service capabilities in microbiology[17] - The company is committed to optimizing its global industrial chain deployment to achieve sustainable profitability[17] Shareholder Information - The total number of common shareholders at the end of the reporting period is 26,203, with the top 10 shareholders holding a combined 78.69% of shares[18] - Shenzhen Le Ren Technology Co., Ltd. holds 32.31% of shares, amounting to 474,029,899 shares, while Urumqi Jintian Soil Equity Investment Partnership holds 27.81% with 408,041,280 shares[19] - The top shareholder relationships indicate that Shenzhen Le Ren Technology Co., Ltd. and Urumqi Jintian Soil Equity Investment Partnership are linked through common partners, Li Li and Li Tan[19]